Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $753.60M.
ENTERPRISE VALUE (EV)
$753.60M
Avalo Therapeutics, Inc.
Market Cap
$767.46M
Enterprise Value (EV)
$753.60M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | $767.46M | $753.60M |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.32M | $745.82M |
| Design Therapeutics, Inc. (DSGN)vs › | $775.72M | $764.84M |
| Geron Corporation (GERN)vs › | $776.24M | $835.74M |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | $2.80B |
| Candel Therapeutics, Inc. (CADL)vs › | $749.55M | $597.51M |
| Cytek Biosciences, Inc. (CTKB)vs › | $786.48M | $739.09M |
| Anteris Technologies Global Corp. (AVR)vs › | $734.10M | $480.04M |
| Achieve Life Sciences, Inc. (ACHV)vs › | $719.64M | $686.63M |
| Gyre Therapeutics, Inc. (GYRE)vs › | $819.44M | $779.57M |
Market Cap
$767.46M
Total Debt
$2.00M
Cash
$15.86M
Enterprise Value
$753.60M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
